IBEC and IRB Barcelona projects awarded funds from the 2017 edition of La Marató de TV3 Blog Post

Yesterday, La Fundació  Marató de TV3 announced the 36 projects awarded funding in the 2017 edition of the telethon, dedicated to infectious diseases. Among them is a project headed by Ernest Giralt, from the Institute for Research in Biomedicine (IRB Barcelona) and Jordi Vila, from the Barcelona Institute for Global Health (ISGlobal), and two projects led by Xavier Fernandez-Busquets and Antonio Juarez from the Institute for Bioengineering of Catalonia (IBEC).

 

Three innovation projects at IRB Barcelona are granted funding for market development Blog Post

The Catalan’ Government’s Agency for Management and of University and Research Grants (Agencia de Gestió i Ajuts Universitaris i de Recerca (AGAUR)) has awarded around 220,000 euros to three innovation projects underway at the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park. These funds have been provided through the 2016 Knowledge Industry grant call, a programme cofunded by European Regional Development Funds (ERDFs) devoted to Catalonia in the period 2014-2020.

 

Gate2Brain of IRB Barcelona is one of the projects supported by the RecerCaixa Programme Blog Post

The project “Gate2Brain, peptide shuttles for protein replacement therapy in Friedreich’s ataxia“, led by Ernest Giralt, head of the Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona) –based in the PCB– and full professor of the University of Barcelona, and by Javier Díaz Nido, at the Centro de Biología Molecular Severo Ochoa (CBMSO), has been awarded funding from the RecerCaixa Programme—an initiative of the Obra Social “la Caixa” with the collaboration of the Associació Catalana d’Universitats Públiques(ACUP).

 

 

The Barcelona City Council awards Ernest Giralt with the “Ciutat de Barcelona” award Blog Post

Ernest Giralt, group leader of the Design, synthesis and structure of peptides and proteins Laboratory at IRB Barcelona –located at the PCB– and  professor in the Department of Organic Chemistry at the University of Barcelona has received  the ‘Ciutat de Barcelona’ Award in the category of Experimental Sciences and Technology. The awards ceremony will take place on Tuesday, February 10 in the City Council, and will be chaired by Mayor Xavier Trias.

New research front to tackle Friedreich’s Ataxia Blog Post

The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona) located at PCB. The long-term goal of the project is to achieve an injectable frataxin treatment able to reach the brain. Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.

 

Iproteos closes a round of funding valued at 1.5 millon Euros Blog Post

Iproteos – based at the Barcelona Science Park– has closed a round of funding valued at 1.5 millon Euros, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech ASCIL Biopharm. The company will set aside this injection of capital to the completion of the regulatory preclinical phase of his compound, a first-in-class drug for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound is one of the few that are being developed around the world to halt and reverse the cognitive impairment caused by this disease.

 

Iproteos, the first biotech to launch an equity crowdfunding campaign in Spain Blog Post

The Catalan biotech Iproteos –based in the Parc Cientific de Barcelona (PCB)– has launched an innovative funding campaign based on equity crowdfunding- through the Creoentuproyecto.com platform– which aims to raise 100,000 € to complete the non-regulatory preclinical stage of its compound IPR019. This compound is one of the 20 drugs in the world that are being developed to slow-down the progression of schizophrenia and revert the cognitive deficits of this condition. Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the transfer of a technology generated at Institute for Research in Biomedicine (IRB Barcelona) and the University of Barcelona (UB). In addition, the Bosch i Gimpera Foundation (FBG) has given advice on the definition of the business plan and negotiated the technology.